Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.

Abstract

To evaluate haematopoietic stem cell transplantation (HSCT) in children and adolescents, we reviewed the records of 47 patients who were ≤18 years, had relapsed or refractory anaplastic large cell lymphoma, and received HSCT between 1990 and 2010. At HSCT, complete remission (CR) was less common in allogeneic HSCT recipients (n = 24) than in autologous HSCT recipients (n = 23) (P = 0·01). The autologous and allogeneic HSCT groups differed in terms of 5-year event-free survival (EFS) (38% vs. 50%, P = 0·63), cumulative incidence of progress or relapse (49% vs. 28%, P = 0·25), and treatment-related mortality (12% vs. 25%, P = 0·40). However, these differences were not significant. Patients with non-CR at autologous HSCT had a significantly lower EFS rate (14% vs. 48%, P = 0·03). Conversely, although those with non-CR at allogeneic HSCT had a lower EFS rate, this was not significant (44% vs. 63%, P = 0·26). Reduced-intensity conditioning regimens were used for three of the 16 allogeneic HSCTs received by patients with non-CR. These three patients achieved CR, surviving 32-65 months after HSCT. These results demonstrated that allogeneic HSCT might be a treatment option for patients who do not achieve CR through conventional chemotherapy.

• Authors: Reiji Fukano, Tetsuya Mori, Ryoji Kobayashi, Tetsuo Mitsui, Naoto Fujita, Fuminori Iwasaki, Junji Suzumiya, Motoaki Chin, Hiroaki Goto, Yoshiyuki Takahashi, Junichi Hara, Yong-Dong Park, Masami Inoue, Yuhki Koga, Jiro Inagaki, Hisashi Sakamaki, Souichi Adachi, Keisei Kawa, Koji Kato, Ritsuro Suzuki
• Journal: British journal of haematology (Br J Haematol) Vol. 168 Issue 4 Pg. 557-63 (Feb 2015) ISSN: 1365-2141 [Electronic] England
• PMID: 25312752 (Publication Type: Evaluation Study, Journal Article)
• Copyright: © 2014 John Wiley & Sons Ltd.

Topics

• Adolescent
• Allografts
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Combined Modality Therapy
• Disease-Free Survival
• Drug Resistance, Neoplasm
• Graft vs Host Disease (epidemiology, etiology)
• Hematopoietic Stem Cell Transplantation
• Humans
• Incidence
• Japan (epidemiology)
• Lymphoma, Large-Cell, Anaplastic (drug therapy, therapy)
• Recurrence
• Retrospective Studies
• Salvage Therapy
• Transplantation Conditioning
• Transplantation, Autologous